Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Enveda 融资 3.11 亿美元，旨在将更多源自自然的 AI 药物推向临床试验

Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation. The fresh funding, which was led by Catalio Capital Management, with participation from Iconiq and others, doubles the valuation Enveda achieved 12 months ago.

Enveda 是一家利用人工智能在自然界中发现新药的生物技术初创公司，近日完成了 3.11 亿美元的 E 轮融资，估值达到 20 亿美元。本轮融资由 Catalio Capital Management 领投，Iconiq 等机构跟投，其估值较 12 个月前翻了一番。

The idea behind Enveda is that powerful medicines could be harnessed from plants and microbes, rather than synthesized from scratch in a lab. Viswa Colluru, an early employee of Recursion Pharmaceuticals, founded Enveda in 2019 to speed up the process of discovering these new drugs using AI and other techniques.

Enveda 的核心理念是：强效药物可以从植物和微生物中提取，而不是在实验室中从零开始合成。Enveda 由 Recursion Pharmaceuticals 的早期员工 Viswa Colluru 于 2019 年创立，旨在利用人工智能和其他技术加速这些新药的发现过程。

While AI hasn’t yet produced any FDA-approved drugs, Enveda is among the wave of companies advancing AI-discovered candidates into human clinical trials. The startup is currently testing several drugs in patients, including one targeting severe skin conditions and another designed to help maintain weight loss after stopping GLP-1s.

尽管目前人工智能尚未产出任何获得 FDA 批准的药物，但 Enveda 属于那一批正将 AI 发现的候选药物推进至人体临床试验的公司。该初创公司目前正在对几种药物进行患者测试，其中包括一种针对严重皮肤病的药物，以及另一种旨在帮助患者在停用 GLP-1 类药物后维持减重效果的药物。